REGENERATING LARGE BONE DEFECTS

Projektinformationen

REGENERBONE

ID Finanzhilfevereinbarung: 790435

DOI

10.3030/790435

Das Projekt endete am 31 August 2019

EK-Unterschriftsdatum 22 März 2018

Startdatum 1 April 2018

Enddatum 30 September 2019

Finanziert unter

• EXCELLENT SCIENCE - European Research Council (ERC)

Gesamtkosten

€ 149 998,71

EU-Beitrag

€ 149 998,71

Koordiniert durch

INSTITUT POLYTECHNIQUE DE GRENOBLE
France

Periodic Reporting for period 1 - REGENERBONE (REGENERATING LARGE BONE DEFECTS)

Berichtszeitraum: 2018-04-01 bis 2019-09-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

In the field of orthopedics and maxillo-facial surgeries, there is still no satisfying solution to repair critical size bone defects. Autograft, which is the current gold standard, presents several drawbacks, including prolonged pain on donor site and higher infection risks. It needs to be replaced by efficient, safe and easy-to-use strategies. Some synthetic bone grafts are providing mechanical and osteoconductive properties, but there is a need to introduce a bioactive molecules, such as a growth factor or a peptide, to trigger actively bone repair. These “orthobiologics” products are appealing since they trigger stem cell activation in situ. There are several approved products containing orthobiologics on the market for bone regeneration, but the physiological delivery of orthobiologics remains a challenge: severe adverse effect have been reported due to the supra-physiological dose of biologics used. In addition these product do not provide structural properties which is necessary for critical size defect reconstruction. Ideally the carrier for the bioactive molecules should be appropriate and enable a spatially/temporally-controlled molecules delivery with physiological dose.
Our nanomedicine technology consists of an osteoinductive biomimetic films that can be deposited on architectured implant of any shape and material (ceramics, polymers, metals). The aim of REGENERBONE is to advance our technology toward a clinical application in maxillo-facial surgery and orthopedics. We have conducted pre-clinical trials in large animals, done a market search, and have secured the sourcing of proteins. We have also build a first draft of a business model. We are now looking for a CEO to pursue the clinical translation of our innovative nanomedicine technology in the frame of a start-up company.